View Older Stories View More Recent Stories

Jun 3, 2024 05:56PM Form SC 13G/A Inhibrx, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Jun 3, 2024 02:30PM Mythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2024 08:00AM Neurona Therapeutics to Participate in Jefferies Global Healthcare Conference
May 25, 2024 06:51AM HI-Bio Announces Positive Results from Phase 2 Study of Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
May 24, 2024 07:02AM HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress
May 23, 2024 08:17AM Mythic Therapeutics to Present Data from Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 22, 2024 09:00AM Pearl Health releases Top 50 Value-Based Care Thinkers of 2024
May 22, 2024 07:31AM Biogen (BIIB) to Acquire Human Immunology Biosciences for $1.15B Upfront Plus Milestone Payments
May 22, 2024 07:30AM Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 15, 2024 07:26PM Hedge fund Coatue scraps its Apple stake in Q1, while Viking built its position
May 15, 2024 04:06PM Form 13F-HR VIKING GLOBAL INVESTORS For: Mar 31
May 9, 2024 12:00PM With Vim as a Strategic Technology Partner, Pearl Health Launches Enhanced EHR Experience
May 8, 2024 09:49AM AbCellera Biologics (ABCL) PT Lowered to $7 at KeyBanc
May 7, 2024 04:05PM AbCellera Reports Q1 2024 Business Results
May 1, 2024 09:00AM AbCellera, Viking Global Investors, and ArrowMark Partners Collaborate to Launch New Biotech Companies
May 1, 2024 07:00AM Ayana Bio Awarded National Institutes of Health Grant to Harness Neuroprotective Benefits from Plant Cell-Cultivated Saffron
Apr 30, 2024 10:00AM Mythic Therapeutics Announces Publication of Preclinical Data Highlighting the Differentiating Properties of MYTX-011 in Molecular Cancer Therapeutics
Apr 12, 2024 10:54AM Revive Environmental’s PFAS Annihilator® Fit to Destroy PFAS as Outlined by New Environmental Protection Agency (EPA) Guidelines
Apr 8, 2024 12:00PM Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting
Apr 3, 2024 06:00AM Diagonal Therapeutics Launches with $128 Million in Financing to Pioneer a New Approach to Discovering and Developing Agonist Antibodies to Tackle the Underlying Causes of Severely Debilitating Diseas
Mar 28, 2024 07:00AM Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
Mar 20, 2024 06:05PM Form SC 13G/A STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
Mar 20, 2024 06:05PM Form 3 STANDARD BIOTOOLS INC. For: Mar 18 Filed by: Viking Global Opportunities Illiquid Investments Sub-Master LP
Mar 18, 2024 03:35PM Battelle and Revive Environmental Technologies Officials Join Ohio Governor Mike DeWine to Announce Kickoff of PFAS Takeback Program
Mar 18, 2024 08:14AM Standard BioTools (LAB) exchanged all outstanding shares of its Series B Convertible Preferred Stock for shares of common stock
Mar 18, 2024 08:12AM Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
Mar 12, 2024 06:00AM Pearl Health and Wellcare Announce Partnership to Advance Value-Based Care Access in Primary Care
Mar 6, 2024 07:00AM Sionna Therapeutics Announces $182 Million Series C Financing to Advance Clinical Development of Novel Small Molecules in Cystic Fibrosis
Mar 1, 2024 04:19PM Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 29, 2024 10:09PM APi Group Corp (APG) Announces Pricing of Upsized Secondary Public Offering of Common Stock
Feb 29, 2024 10:09PM APi Group Announces Pricing of Upsized Secondary Public Offering of Common Stock
Feb 28, 2024 04:44PM Form 4 RayzeBio, Inc. For: Feb 26 Filed by: VIKING GLOBAL INVESTORS LP
Feb 28, 2024 04:39PM Form 4 RayzeBio, Inc. For: Feb 26 Filed by: Viking Global Opportunities Drawdown Portfolio GP LLC
Feb 28, 2024 04:34PM Form SC 13G/A RayzeBio, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Feb 28, 2024 04:22PM APi Group Corporation (APG) Launches 8.13M Share Secondary Offering
Feb 28, 2024 04:22PM APi Group Announces Launch of Secondary Public Offering of Common Stock
Feb 28, 2024 07:23AM APi Group Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Agreement to Retire All Outstanding Series B Preferred Stock from Blackstone and Viking
Feb 26, 2024 04:30PM Mainstay Medical Announces US$125 Million Equity Financing Transaction
Feb 15, 2024 07:27AM Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors
Feb 14, 2024 01:58PM Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31
Feb 14, 2024 10:27AM Form SC 13G/A Pharvaris N.V. Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:26AM Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:25AM Form SC 13G/A APi Group Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:24AM Form SC 13G/A Amylyx Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:23AM Form SC 13G/A Adaptive Biotechnologies Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:22AM Form SC 13G/A Trevi Therapeutics, Inc. Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:21AM Form SC 13G/A Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:19AM Form SC 13G/A Rallybio Corp Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:17AM Form SC 13G/A PepGen Inc. Filed by: VIKING GLOBAL INVESTORS LP
Feb 14, 2024 10:16AM Form SC 13G/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
View More Recent Stories View Older Stories